title: Cholecystokinin regulates the invasiveness of human pancreatic cancer cell lines via protein kinase C pathway.
abstract: We have previously reported that cholecystokinin (CCK) plays an important role in the invasiveness and the production of matrix metalloproteinase-9 (MMP-9) in two human pancreatic cancer cell lines. In this study we investigated the pathway of the invasiveness associated with MMP-9 of those lines regulated by CCK. Two human pancreatic cancer cell lines were treated with CCK-8 alone, CCK-8 and staurosporine, or CCK-8 and indomethacine. The invasiveness and the production of MMP-9 were decreased with staurosporine but not indomethacine. These results suggest that CCK may regulate the invasiveness and the production of MMP-9 via protein kinase C in human pancreatic cancer cell lines.
authors.affiliation: First Department of Internal Medicine, Hiroshima University School of Medicine, Minami-ku, Hiroshima 734-8851, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hirata
authors.forename: A
authors.initials: A
authors.lastname: Tsuchida
authors.forename: T
authors.initials: T
authors.lastname: Iwao
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Matsubara
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Morinaka
authors.forename: Y
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: K
authors.initials: K
authors.lastname: Kariya
authors.forename: G
authors.initials: G
authors.lastname: Kajiyama
mesh_terms: D015153:Blotting, Western; D002766:Cholecystokinin / Q000502:physiology*; D017364:Collagenases / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000096:biosynthesis; D015259:Dopamine Agents / Q000494:pharmacology; D004790:Enzyme Induction; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007124:Immunoenzyme Techniques; D007213:Indomethacin / Q000494:pharmacology; D020780:Matrix Metalloproteinase 9; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology; D012844:Sincalide / Q000494:pharmacology; D019311:Staurosporine / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D016861:Cyclooxygenase Inhibitors; D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D002766:Cholecystokinin; D011493:Protein Kinase C; D017364:Collagenases; D020780:Matrix Metalloproteinase 9; D019311:Staurosporine; D015232:Dinoprostone; D012844:Sincalide; D007213:Indomethacin